Understanding Nektar Therapeutics’ Operational Performance
How Is Nektar Therapeutics Positioned in August? Nektar Therapeutics expects an increase in its general and administrative expenses in 2018 compared to 2017 due to higher noncash stock-based compensation expenses. Nektar Therapeutics saw an operating income of -$50.66 million in the second quarter of 2017 compared to its operating income of $973.6 million in the second quarter of 2018.